A Phase II Study of PTS100 in Primary HCC Patients
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study is being performed to evaluate the efficacy and safety of 20% and 30% PTS100 of
total tumor volume as intra-tumoral injection therapy in primary Hepatocellular Carcinoma
patients who are ineligible for operation or local regional therapy.